Denali
December 13, 2021
Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
Recent News
- Biolexis Therapeutics Advances Breakthrough GLP-1 and AMPK Programs into First-in-Human Clinical Trials
- Rebel Medicine Announces Series A Financing and Investigational New Drug (IND) Application Opening to Advance Non‑Opioid Pain Therapeutic into Clinical Development
- NUSANO STABLE ISOTOPE PROGRAM ENRICHES GADOLINIUM-160 TO 99.2% PURITY
- CancerVax Targets Liver Cancers to Further Showcase Flexibility of Its Universal Platform
- Seek Labs Unveils BioSeeker™
- Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)
